Skip to main content
. 2023 Jun 2;11(6):e006388. doi: 10.1136/jitc-2022-006388

Figure 7.

Figure 7

Expression of ASS1 improves MYXV-based OV. (A) Genomic schematic of recombinant viruses used in this study including MyxPD1/IL-12 and MyxASS1/PD1/IL-12. (B, C) ASS1WT, ASS1KO (KO#1 and KO#4), and A9F1 tumors were established in C57Bl/6J mice and then treated with three doses of either PBS (mock) or 1×105 FFU of MyxPD1/IL-12 or MyxASS1/PD1/IL-12 intratumorally QOD over 5 days. Tumor burden was then monitored QOD in all cohorts. (B) Spaghetti plots tracking individual tumor sizes over time. (C) Overall survival of mice. Statistical significance was determined using log-rank analysis (n=6–9 mice per group). *P<0.05. ASS1, argininosuccinate synthetase 1; IL, interleukin; MyxASS1, MYXV encoding full-length murine ASS1; MYXV, myxoma virus; OV, oncolytic virotherapy; PBS, phosphate-buffered saline; QOD, every other day; WT, wild type.